Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL2679735

COC(C)[n+]1ccn(C)c1.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.32

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3118981 0.88
SCHEMBL372496 0.82
Trifluoromethanesulfonic Acid SCHEMBL3016924 0.82
Bromide SCHEMBL14118309 0.81
SCHEMBL29151641 0.79
SCHEMBL1072763 0.79
SCHEMBL28491835 0.79
Trifluoromethanesulfonic Acid SCHEMBL2028439 0.75
Trifluoromethanesulfonic Acid SCHEMBL28497776 0.73
Trifluoromethanesulfonic Acid SCHEMBL318315 0.73 KCNH2 (0.33) ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252944-B2 Process for preparing heteroaromatic ring compound having N-Rf group DAIKIN INDUSTRIES, LTD. (JP) 2012-08-28 US disclosed
US-8212053-B2 Process for preparing heteroaromatic ring compound having N-Rf group DAIKIN INDUSTRIES, LTD. (JP) 2012-07-03 US disclosed
US-20120116097-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP DAIKIN INDUSTRIES, LTD. (JP) 2012-05-10 US disclosed
US-20100222598-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP DAIKIN INDUSTRIES, LTD. (JP) 2010-09-02 US disclosed
EP-1975157-A1 METHOD FOR PRODUCTION OF HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP Daikin Industries, Ltd. (JP) 2008-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222598-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP CYP2F1, AFF1, AFF2 ACHE 1985/4885
US-20120116097-A1 PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP CYP2F1, AFF1, AFF2 ACHE 1985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.